Impel NeuroPharma Announces U.S. FDA Approval of TRUDHESA™ (Dihydroergotamine Mesylate) Nasal Spray for the Acute Treatment of Migraine

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/22/2026

1. SPCX
2. NVDA
3. ACN
4. USO
5. GOOGL
6. APGE
7. DFTX
8. MU
9. IBM
10. HOOD

Go back to Impel NeuroPharma Announces U.S. FDA Approval of TRUDHESA™ (Dihydroergotamine Mesylate) Nasal Spray for the Acute Treatment of Migraine

Impel Neuropharma (IMPL) PT Raised to $55 at Cowen on FDA Approval

September 3, 2021 10:57 AM EDT

Cowen analyst Ken Cacciatore raised the price target on Impel Neuropharma (NASDAQ: IMPL) to $55.00 (from $35.00) while maintaining an Outperform rating.

The analyst commented, "The FDA has approved Trudhesa for the treatment of acute migraines with a clean label right in line with our... More

Impel NeuroPharma Inc. (IMPL) surges 59% as trading reumes on FDA approval

September 3, 2021 9:18 AM EDT

Impel NeuroPharma Inc. (NASDAQ: IMPL) surges 59% as trading reumes on FDA approval

... More